Categories: News

Inogen to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.


Individuals interested in listening to the conference call may do so by dialing:

US domestic callers (877) 841-3961

Non-US callers (201) 689-8589

Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen’s website at: http://investor.inogen.com/. This webcast will also be archived on the website for 6 months.

A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through March 5, 2024. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13743411.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.

For more information, please visit www.inogen.com.

Contacts

ir@inogen.net

Staff

Recent Posts

NuGen Medical Devices Inc. Announces CFO Transition

Toronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

5 minutes ago

Midmark RTLS launches BLE Sensory Network for smarter, scalable RTLS

New Plug-In BLE Sensors provide a faster, more cost-effective path to facility-wide RTLS coverage with near-room…

6 minutes ago

Vrtly, Inc. Unveils End-to-End In-Practice Marketing Platform, Bridging the “Blind Spot” for Brands in Cash-Pay Healthcare

DANVILLE, Calif., Jan. 30, 2026 /PRNewswire/ -- Vrtly, Inc., the premier point-of-care (POC) marketing platform…

6 minutes ago

Frontage Laboratories Expands Early Phase Clinical Capabilities to Support Global Drug Development

EXTON, Pa., Jan. 30, 2026 /PRNewswire/ -- Frontage Laboratories, Inc. ("Frontage"), a global Contract Research,…

6 minutes ago

MEDITECH Announces the Passing of Founder and Chairman A. Neil Pappalardo

Reflections on his 56-year legacy as a tech pioneer and founder of the EHR industryCANTON,…

3 hours ago